Shin Poong is one of the oldest pharmaceutical companies in Korea. Established after the Korean War, the company’s original mission was to provide high-quality and affordable generic medicines to the Korean people. Now the company has transitioned into an innovative developer of novel first-in-class therapeutics, including a malaria treatment on the WHO’s Essential Medicine List (EML). Its CEO Jei Man Ryu explains how Shin Poong made this transition, its dedication to the health of humankind, and lays out the global ambitions of the company.
Before Shin Poong, other malaria treatments were already being used but faced resistance and safety issues
